Charles River Laboratories International Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 78.25
Dividend & YieldN/A$ (N/A)
Beta 1.33
Market capitalization 11.83B
Operating cash flow 619.64M
ESG Scores unknown

Company description

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Sector: Healthcare - Industry: Diagnostics & Research

Financial Ratios
Quick Ratio1.04
Working Capital1.62
Return On Equity0.15
Debt To Equity1.04
Fixed Asset Ratio0.18
Fixed Interest Cover8.58

Financial data

Financial Statements

Cashflow Statement 2019-12-28 2020-12-26 2021-12-25 2022-12-31
Change To Liabilities 15.26M 38.35M 48.42M 85.46M
Total Cashflows From Investing Activities -681.5M -601.54M -1.44B -607.92M
Net Borrowings 233.87M 30.59M 708.24M 19.79M
Total Cash From Financing Activities 231.94M 47.25M 672.6M -42.4M
Change To Operating Activities 20.64M 39.38M 46.31M -8.92M
Issuance Of Stock 34.55M 46.59M 45.65M 25.11M
Net Income 252.02M 364.3M 390.98M 486.23M
Change In Cash 42.73M -6.93M 13.2M -5.1M
Effect Of Exchange Rate 11.36M 794k 17.73M 25.58M
Total Cash From Operating Activities 480.94M 546.58M 760.8M 619.64M
Depreciation 198.09M 234.92M 265.54M 303.87M
Change To Account Receivables -8.32M -85.63M -26.63M -150.57M
Other Cashflows From Financing Activities -18.39M -5.95M -40.58M -48.65M
Change To Netincome 24.64M -26.38M 61.34M -17.9M
Capital Expenditures -140.51M -166.56M -228.77M -324.73M

Income Statement 2019-12-28 2020-12-26 2021-12-25 2022-12-31
Research Development
Income Before Tax 304.08M 447.11M 480.71M 622.99M
Net Income 252.02M 364.3M 390.98M 486.23M
Selling General Administrative 487.69M 522.59M 582.25M 657.54M
Gross Profit 965.03M 1.07B 1.33B 1.46B
Ebit 387.8M 439.07M 627.53M 658.53M
Operating Income 387.8M 439.07M 627.53M 658.53M
Interest Expense -60.88M -86.43M -73.91M -59.29M
Income Tax Expense 50.02M 81.81M 81.87M 130.38M
Total Revenue 2.62B 2.92B 3.54B 3.98B
Cost Of Revenue 1.66B 1.85B 2.21B 2.51B
Total Other Income ExpenseNet -83.72M 8.04M -146.82M -35.55M
Net Income From Continuing Ops 254.06M 365.31M 398.84M 492.61M
Net Income Applicable To Common Shares 252.02M 364.3M 390.98M 486.23M

Balance Sheet Statement 2019-12-28 2020-12-26 2021-12-25 2022-12-31
Total Liabilities 3.03B 3.35B 4.43B 4.58B
Total Stockholder Equity 1.63B 2.11B 2.53B 2.98B
Other Current Liabilities 242.05M 285.75M 324.08M 418.63M
Total Assets 4.69B 5.49B 7.02B 7.6B
Common Stock 489k 498k 505k 509k
Other Current Assets 55.09M 71.54M 97.31M 107.58M
Retained Earnings 280.33M 625.41M 980.75M 1.43B
Treasury Stock -178.02M -138.87M -164.74M -262.06M
Cash 238.01M 228.42M 241.21M 233.91M
Total Current Liabilities 710.18M 839.75M 1.03B 1.09B
Other Stockholder Equity -178.02M -138.87M -164.74M -262.06M
Property, Plant, and Equipment 1.18B 1.3B 1.58B 1.86B
Total Current Assets 1.02B 1.2B 1.27B 1.44B
Net Tangible Assets -595.39M -482.17M -1.24B -828.88M
Net Receivables 514.03M 617.74M 642.88M 752.39M
Accounts Payable 111.5M 122.47M 198.13M 205.91M


Insider Transactions

Here are the insider transactions of stock shares related to Charles River Laboratories International Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
WALLMAN RICHARD F.Purchase at price 220.73 per share.D2023-02-23Director1.75k
GIRSHICK BIRGITSale at price 246.13 - 256.48 per share.D2023-02-16Chief Operating Officer3.21k
GIRSHICK BIRGITConversion of Exercise of derivative security at price 109.34 per share.D2023-02-16Chief Operating Officer3.21k
PARISOTTO SHANNON MSale at price 246.02 - 257.05 per share.D2023-02-16Officer4.56k
PARISOTTO SHANNON MConversion of Exercise of derivative security at price 109.34 per share.D2023-02-16Officer4.56k
FOSTER JAMES CSale at price 250.00 - 250.16 per share.D2023-02-15Chief Executive Officer20k
FOSTER JAMES CStock Award(Grant) at price 0.00 per share.D2023-01-27Chief Executive Officer49.73k
KNELL MICHAEL GUNNARStock Award(Grant) at price 0.00 per share.D2023-01-27Officer2.1k
CREAMER VICTORIA LStock Award(Grant) at price 0.00 per share.D2023-01-27Officer7.23k
BARBO WILLIAM DStock Award(Grant) at price 0.00 per share.D2023-01-27Officer7.86k
GIRSHICK BIRGITStock Award(Grant) at price 0.00 per share.D2023-01-27Chief Operating Officer8.44k
LAPLUME JOSEPH WStock Award(Grant) at price 0.00 per share.D2023-01-27Officer8.68k
PARISOTTO SHANNON MStock Award(Grant) at price 0.00 per share.D2023-01-27Officer4.82k
THOMPSON CRAIG BStock Award(Grant) at price 0.00 per share.D2023-01-03Director244
WALLMAN RICHARD F.Purchase at price 218.90 per share.D2022-12-02Director1.5k
BARBO WILLIAM DSale at price 218.28 - 221.08 per share.D2022-12-02Officer3.21k
BARBO WILLIAM DConversion of Exercise of derivative security at price 109.34 per share.D2022-12-02Officer3.21k
LAPLUME JOSEPH WSale at price 223.06 - 224.85 per share.D2022-12-01Officer6.41k
LAPLUME JOSEPH WConversion of Exercise of derivative security at price 109.34 per share.D2022-12-01Officer6.41k
KNELL MICHAEL GUNNARSale at price 248.59 per share.D2022-11-16Chief Financial Officer855
KNELL MICHAEL GUNNARConversion of Exercise of derivative security at price 109.34 per share.D2022-11-16Chief Financial Officer855
BARBO WILLIAM DStock Gift at price 0.00 per share.D/I2022-11-15Officer591
PARISOTTO SHANNON MSale at price 249.90 per share.D2022-11-15Officer2.28k
PARISOTTO SHANNON MConversion of Exercise of derivative security at price 109.34 per share.D2022-11-15Officer2.28k
LAPLUME JOSEPH WSale at price 216.36 per share.D2022-11-04Officer534
LAPLUME JOSEPH WSale at price 226.13 per share.D2022-08-05Officer200
LAPLUME JOSEPH WStock Gift at price 0.00 per share.D2022-07-06Officer195
FOSTER JAMES CStock Gift at price 0.00 per share.D2022-06-06Chief Executive Officer2k
KNELL MICHAEL GUNNARStock Award(Grant) at price 0.00 per share.D2022-05-27Officer491
CREAMER VICTORIA LStock Award(Grant) at price 0.00 per share.D2022-05-27Officer1.49k
BARBO WILLIAM DStock Award(Grant) at price 0.00 per share.D2022-05-27Officer1.49k
GIRSHICK BIRGITStock Award(Grant) at price 0.00 per share.D2022-05-27Chief Operating Officer2.46k
LAPLUME JOSEPH WStock Award(Grant) at price 0.00 per share.D2022-05-27Officer1.66k
PEASE FLAVIA H.Stock Award(Grant) at price 0.00 per share.D2022-05-27Chief Financial Officer1.64k
WALLMAN RICHARD F.Stock Award(Grant) at price 0.00 per share.D2022-05-11Director935
REESE C RICHARDStock Award(Grant) at price 0.00 per share.D2022-05-11Director957
MASSARO GEORGE EStock Award(Grant) at price 0.00 per share.D2022-05-11Director575
WILSON VIRGINIA MStock Award(Grant) at price 0.00 per share.D2022-05-11Director575
BERTOLINI ROBERT JStock Award(Grant) at price 0.00 per share.D2022-05-11Director980
MACKAY MARTINStock Award(Grant) at price 0.00 per share.D2022-05-11Director841
KOCHEVAR DEBORAH TURNERStock Award(Grant) at price 0.00 per share.D2022-05-11Director575
ANDREWS NANCY CStock Award(Grant) at price 0.00 per share.D2022-05-11Director575
LLADO GEORGE SR.Stock Award(Grant) at price 0.00 per share.D2022-05-11Director867
MASSARO GEORGE ESale at price 228.62 - 238.06 per share.D2022-05-09Director178
PEASE FLAVIA H.Stock Award(Grant) at price 0.00 per share.D2022-05-02Officer5.18k
BARBO WILLIAM DStock Gift at price 0.00 per share.D2022-03-11Officer754
SMITH DAVID ROSSSale at price 281.49 - 285.16 per share.D2022-03-03Chief Financial Officer8.96k
SMITH DAVID ROSSConversion of Exercise of derivative security at price 109.34 - 179.66 per share.D2022-03-03Chief Financial Officer8.96k
SMITH DAVID ROSSStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Financial Officer5.15k
FOSTER JAMES CSale at price 283.89 - 295.70 per share.D2022-02-23Chief Executive Officer20.3k
FOSTER JAMES CConversion of Exercise of derivative security at price 109.34 per share.D2022-02-23Chief Executive Officer20.3k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Charles River Laboratories International Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Charles River Laboratories International Inc

Here is the result of two systematic investment strategies applied to Charles River Laboratories International Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Charles River Laboratories International Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Charles River Laboratories International Inc:

Charles River Laboratories International Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 163.88% on the backtest period.

Performance at glance

Performance

163.88 %

Latent gain

3984.67 $

Invested capital

2431.53 $

Annualized return

39.58 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Charles River Laboratories International Inc

This is the result of two momentum investment strategies applied to Charles River Laboratories International Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Charles River Laboratories International Inc

The following chart shows all the entries opened by the momentum investment system on Charles River Laboratories International Inc:

Charles River Laboratories International Inc momentum entries
  • The first momentum investment strategy would give 220.32% of return on Charles River Laboratories International Inc. That represents 13239.36$ of latent gain with 6009.24$ of employed capital.
  • The second momentum investment strategy would give 267.1% of return on Charles River Laboratories International Inc. That represents 8669.9$ of latent gain with 3245.9$ of employed capital.
Performance at glance (1Q Momentum)

Performance

220.32 %

Latent gain

13239.36 $

Invested capital

6009.24 $

Annualized return

63.48 %
Performance at glance (2Q Momentum)

Performance

267.1 %

Latent gain

8669.9 $

Invested capital

3245.9 $

Annualized return

72.98 %

Momentum equity curve on Charles River Laboratories International Inc

The following chart shows the equity curve of the two momentum strategies applied to Charles River Laboratories International Inc:

Charles River Laboratories International Inc momentum equity

Note: the dividends potentially given by Charles River Laboratories International Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Charles River Laboratories International Inc

The following chart shows the employed capital evolution of the two momentum strategies on Charles River Laboratories International Inc since the beginning:

Charles River Laboratories International Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Charles River Laboratories International Inc

Buy the dip entry openings on Charles River Laboratories International Inc

Charles River Laboratories International Inc

The performance achieved by the robo-advisor on Charles River Laboratories International Inc is 135.84%. That represents 791.92$ of latent gain with 582.98$ of employed capital. The following chart shows Charles River Laboratories International Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Charles River Laboratories International Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

135.84 %

Latent gain

791.92 $

Invested capital

582.98 $

Annualized return

63.48 %

Equity curve of the strategy applied to Charles River Laboratories International Inc

The following chart shows the result of the investment strategy applied to Charles River Laboratories International Inc:

Charles River Laboratories International Inc

Note: the dividends potentially given by Charles River Laboratories International Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Charles River Laboratories International Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Charles River Laboratories International Inc:

Charles River Laboratories International Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Charles River Laboratories International Inc

In this section, I will compare the three previous investment strategies applied to Charles River Laboratories International Inc.

Equity curve comparison on Charles River Laboratories International Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Charles River Laboratories International Inc investment strategy comparison

Employed capital comparison on Charles River Laboratories International Inc

Charles River Laboratories International Inc investment comparison

Performance comparison on Charles River Laboratories International Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 163.88% 3984.67$ 2431.53$ 39.58%
Momentum 1 quarter 220.32% 13239.36$ 6009.24$ 56.49%
Momentum 2 quarters 267.1% 8669.9$ 3245.9$ 72.98%
Non-directional 135.84% 791.92$ 582.98$ 63.48%
Annualized return comparison

Automatic investment

39.58 %

Momentum 1Q

72.98 %

Momentum 2Q

72.98 %

Non-directional

63.48 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Charles River Laboratories International Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • Impac Mortgage Holdings Inc

  • Note: The algorithm computes the probability of correlation between Charles River Laboratories International Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Charles River Laboratories International Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Charles River Laboratories International Inc
    Country United States
    City Wilmington
    Address 251 Ballardvale Street
    Phone 781 222 6000
    Website www.criver.com
    FullTime employees 20000
    Industry Diagnostics & Research
    Sector Healthcare
    Exchange XNYS
    Ticker CRL
    Market www.nyse.com

    Charles River Laboratories International Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown